ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE.
May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones.
May 2, 2016
April Deals May Flower Future Growth
Image Source: Iqbal Osman. A series of mergers and acquisitions were announced in late April. Will the wave of deal making provide too big a shock to acquirers, or will their future growth trajectories flower? Let’s take a quick look at some of the deals and their impact on the companies involved.
Apr 5, 2016
Treasury Erects Iron Tax Curtain
Image Description/Source: Berlin Wall, 1963; Roger. “If history is any guide, it would seem that tax lawmakers may want to think about the current political agenda’s similarities with respect to that of a “new” Berlin Wall--not one built of barbed wire but of prohibitive, restrictive tax laws--and whether such measures make sense in light of the events of the late 1980s.” – Valuentum Securities
Mar 23, 2016
What Gilead’s Patent Miscue Means for Shareholders
Image Source: Gilead. Not much…right now, but we’re sleeping better at night not including shares in the newsletter portfolios.
Feb 22, 2016
Key Treatment Momentum Drives Big Pharma
Let’s take a look at the recent results of some of the biggest names in Big Pharma.
Feb 2, 2016
Early Read: Gilead Guides Revenue to Decline in 2016, Below Consensus
The growth spurt may be over, and we’re most worried about the back half of this decade.
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…
Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?
Sep 28, 2015
Biotechs Bruised
If one is gambling on the drugs of the future, then one must also deal with the uncertainties of the present. Regulatory risk has taken the air out of the biotech space.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.